Experience with peritoneal cytology in the management of gynecologic malignancies

Keettel, William C.; Pixley, Edna; Buchsbaum, Herbert J.

doi:10.1016/0002-9378(74)90359-7

Cited by 96 publications

(28 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a negative control, norCytologic examination of peritoneal fluids is an important tool in detecting intraperitoneal dissemination of genital tract cancers. Ovarian cancer patients are well-known to show the highest percentage of malignant peritoneal cytology, which reflects clinical stage, intraperitoneal metastasis and patient survival (Keettel et al 1974;Zuna and Behrens 1996). In many cases, however, the differentiation of reactive mesothelial cells (RM) from neoplasms in peritoneal fluids cannot always be made definitively on morphology alone (Fox 1993).…”

Section: Methodsmentioning

confidence: 99%

Ber-EP4 and Anti-Calretinin Antibodies: A Useful Combination for Differential Diagnosis of Various Histological Types of Ovarian Cancer Cells and Mesothelial Cells

Okamoto

Itō

Sasano

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

The differential diagnosis between reactive mesothelial cells and ovarian carcinoma cells is often difficult in cytologic specimens. Immunocytochemical procedures have been utilized in assisting this differential diagnosis, with limitations. Furthermore, previous studies examined only serous type but not other histological types of ovarian carcinoma cases. Therefore, we evaluated the practical value of various epithelial and mesothelial markers in differential diagnosis of these two types of cells. Various types of ovarian carcinoma (serous, n = 22; mucinous, n = 10; endometrioid, n = 7; clear cell, n = 10) and benign mesothelial tissues (n = 15) were studied by immunohistochemistry. We then studied effective panels of antibodies by immunohistochemistry in 43 cytologic specimens of ascites or peritoneal lavage fluid consisting of 20 reactive mesothelium and 23 adenocarcinomas of the ovary. In the tissue specimens, Ber-EP4, a monoclonal antibody of epithelial antigen, and a polyclonal antibody against calretinin, which is expressed in mesothelium, are used in differentiating reactive mesothelial cells from ovarian carcinoma. In cytologic specimens, the sensitivity and specificity of Ber-EP4 were 100% and 90%, respectively. The sensitivity and specificity of the anti-calretinin antibody were 90% and 91%, respectively. Using multiple regression analysis, the correlation coefficient between epithelial antigen and calretinin reactivity was r = 0.938, with a significance level of p < 0.0001. In conclusion, the combined immunostaining of cytologic specimens for Ber-EP4 and the anti-calretinin antibody is helpful for the differential diagnosis between mesothelial cells and not only serous type, but also mucinous, endometrioid and clear cell types of ovarian cancer cells.peritoneal cytology; reactive mesothelial cell; ovarian carcinoma; Ber-EP4; calretinin

show abstract

Section: Methodsmentioning

confidence: 99%

Ber-EP4 and Anti-Calretinin Antibodies: A Useful Combination for Differential Diagnosis of Various Histological Types of Ovarian Cancer Cells and Mesothelial Cells

Okamoto

Itō

Sasano

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Cytologic evaluation of cervical, vaginal, or peritoneal fluids (15)(16)(17)(18), pelvic examination (19)(20)(21), transabdominal, transvaginal, and color Doppler sonography (22,23), and numerous biomarkers (24,25) have been studied as potential screening and diagnostic tests for EOC. However, these modalities are not endowed individually with sufficient test sensitivity and specificity (accuracy) to be recommended for population-based screening of ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer

Baron

Boardman

Lafky³

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecologic cancers in the United States. Because women who are diagnosed with early stage disease have a better prognosis than women diagnosed with late stage disease, early detection represents a potentially practical approach to reduce the mortality associated with EOC. Unfortunately, no single screening test has proven to be effective for this purpose, and a valid and feasible screening program to detect early stage EOC in the general population has not yet been devised. Consequently, research has focused on coupling two or more screening modalities to improve program validity and feasibility. Serum cancer antigen 125 (CA125) and a soluble isoform of the epidermal growth factor receptor (p110 sEGFR) have been studied individually as biomarkers of ovarian cancer. In this study, we compare serum CA125 levels and sEGFR concentrations in women with EOC to women with benign gynecologic conditions of ovarian and non-ovarian origin. We show that serum sEGFR concentrations are lower in patients with EOC than in women with benign gynecologic conditions, whereas serum CA125 levels are higher in patients to EOC compared with women with benign gynecologic conditions. These data also reveal that age and serum sEGFR concentrations modify the association between CA125 levels and EOC versus benign gynecologic disease. Hence, age-and sEGFR-dependent CA125 cutoff thresholds improve the ability of CA125 to discern EOC patients from women with benign ovarian tumors and non-ovarian gynecologic conditions. Our analyses show that parallel testing with fixed sEGFR and CA125 cutoff thresholds optimizes sensitivity to detect EOC, whereas serial testing with age-and sEGFR-dependent CA125 cutoff thresholds optimizes test specificity, and overall accuracy to discern patients with EOC from women with benign ovarian and non-ovarian gynecologic conditions. The combined use of serologic sEGFR and CA125, thus, has improved utility for screening and diagnosing EOC, which may increase the positive predictive value of a multimodal screening program that incorporates these biomarkers to detect and subsequently differentiate benign from malignant ovarian tumors. (Cancer Epidemiol Biomarkers Prev 2005;14(2):306 -18)

show abstract

“…[3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] The significance of positive results, especially in patients with early stage endometrial carcinoma, remains highly elusive. [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] The current study was designed to estimate the incidence of positive PW in patients with endometrial carcinoma and to correlate positive PW cytology with various pathologic parameters.…”

mentioning

confidence: 99%

Peritoneal Washings in Endometrial Carcinoma

Shi

Barakat

et al. 2000

Acta Cytologica

View full text Add to dashboard Cite

Experience with peritoneal cytology in the management of gynecologic malignancies

Cited by 96 publications

References 8 publications

Ber-EP4 and Anti-Calretinin Antibodies: A Useful Combination for Differential Diagnosis of Various Histological Types of Ovarian Cancer Cells and Mesothelial Cells

Ber-EP4 and Anti-Calretinin Antibodies: A Useful Combination for Differential Diagnosis of Various Histological Types of Ovarian Cancer Cells and Mesothelial Cells

Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer

Peritoneal Washings in Endometrial Carcinoma

Contact Info

Product

Resources

About